A study of almost 200,000 young females who received the quadrivalent human papilloma virus vaccine found that immunization was associated only with same-day syncope and skin infections in the two weeks after vaccination. These findings support the general safety of routine vaccination with HPV4 in a clinical care setting to prevent cervical and other genital and reproductive cancers.